{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:45Z","timestamp":1787839185284,"version":"build-2784847793"},"reference-count":134,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Recent advances in therapeutics are now providing a wide range of options for adults and children living with hemophilia. Although therapeutic choices are also increasing for the youngest individuals with severe disease, challenges remain about early management decisions, as supporting data are currently limited. Parents and healthcare professionals are tasked with helping children achieve an inclusive quality of life and maintain good joint health into adulthood. Primary prophylaxis is the gold standard to optimize outcomes and is recommended to start before 2 years of age. A range of topics need to be discussed with parents to aid their understanding of the decisions they can make and how these will affect the management of their child\/children. For those with a family history of hemophilia, prenatal considerations include the possibility of genetic counseling, prenatal investigations, and planning for delivery, together with monitoring of the mother and neonate, as well as diagnosis of the newborn and treatment of any birth-associated bleeding. Subsequent considerations, which are also applicable to families where infant bleeding has resulted in a new diagnosis of sporadic hemophilia, involve explaining bleed recognition and treatment options, practical aspects of initiating\/continuing prophylaxis, dealing with bleeds, and ongoing aspects of treatment, including possible inhibitor development. Over time, optimizing treatment efficacy, in which individualizing therapy around activities can play a role, and long-term considerations, including retaining joint health and tolerance maintenance, become increasingly important. The evolving treatment landscape is creating a need for continually updated guidance. Multidisciplinary teams and peers from patient organizations can help provide relevant information. Easily accessible, multidisciplinary comprehensive care remains a foundation to care. Equipping parents early with the knowledge to facilitate truly informed decision-making will help achieve the best possible longer-term health equity and quality of life for the child and family living with hemophilia.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Plain language summary<\/jats:title>\n                    <jats:p>Points to be taken into account to help families make decisions to best care for children born with hemophilia Medical advances are providing a range of treatment options for adults and children with hemophilia. There is, however, relatively limited information about managing newborns with the condition. Doctors and nurses can help parents to understand the choices for infants born with hemophilia. We describe the various points doctors and nurses should ideally discuss with families to enable informed decision-making. We focus on infants who require early treatment to prevent spontaneous or traumatic bleeding (prophylaxis), which is recommended to start before 2 years of age. Families with a history of hemophilia may benefit from discussions before pregnancy, including how an affected child would be treated to protect against bleeds. When mothers are pregnant, doctors can explain investigations that can provide information about their unborn child, plan for the birth, and monitor mother and baby to minimize bleed risks at delivery. Testing will confirm whether the baby is affected by hemophilia. Not all infants with hemophilia will be born to families with a history of the condition. Identification of hemophilia for the first time in a family (which is \u2018sporadic hemophilia\u2019) occurs in previously undiagnosed infants who have bleeds requiring medical advice and possibly hospital treatment. Before any mothers and babies with hemophilia are discharged from hospital, doctors and nurses will explain to parents how to recognize bleeding and available treatment options can be discussed. Over time, ongoing discussions will help parents to make informed treatment decisions: \u2022\u2003When and how to start, then continue, prophylaxis. \u2022\u2003How to deal with bleeds (reinforcing previous discussions about bleed recognition and treatment) and other ongoing aspects of treatment. \u2003\u25cb\u2003For instance, children may develop neutralizing antibodies (inhibitors) to treatment they are receiving, requiring a change to the planned approach. \u2022\u2003Ensuring treatment remains effective as their child grows, considering the varied needs and activities of their child.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207231165857","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T01:21:30Z","timestamp":1681780890000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Considerations for shared decision management in previously untreated patients with hemophilia A or B"],"prefix":"10.1177","volume":"14","author":[{"given":"Jan","family":"Astermark","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, Lund University, and Department of Hematology, Oncology and Radiation Physics, Sk\u00e5ne University Hospital, Jan Waldenstr\u00f6ms gata 14, SE-205 02 Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-9157","authenticated-orcid":false,"given":"Jan","family":"Blatn\u00fd","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, University Hospital Brno and Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-2439","authenticated-orcid":false,"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[{"name":"Clinical and Molecular Hemostasis, Department of Pediatrics, University Hospital Frankfurt, Goethe University, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"C\u00e9dric","family":"Hermans","sequence":"additional","affiliation":[{"name":"Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques Universitaires Saint-Luc, Universit\u00e9 catholique de Louvain (UCLouvain), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario La Paz, Aut\u00f3noma University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-8598","authenticated-orcid":false,"given":"Daniel P.","family":"Hart","sequence":"additional","affiliation":[{"name":"The Royal London Hospital Haemophilia Centre, Barts and the London School of Medicine, QMUL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"bibr1-20406207231165857","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115709"},{"key":"bibr2-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.17.x"},{"key":"bibr3-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"bibr4-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"bibr5-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01463.x"},{"key":"bibr6-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01281.x"},{"key":"bibr7-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"bibr8-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-015-0562-x"},{"key":"bibr9-20406207231165857","unstructured":"Alabek M, Mohan R, Raia M. Genetic counselling for Hemophilia. Treatment of hemophilia monograph no. 25, https:\/\/www1.wfh.org\/publications\/files\/pdf-1160.pdf (2015, accessed November 2022)."},{"key":"bibr10-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1055\/a-1141-1252"},{"key":"bibr11-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1177\/1076029618807583"},{"key":"bibr12-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13502"},{"key":"bibr13-20406207231165857","unstructured":"UKHCDO. Clinical genetics services for haemophilia, http:\/\/www.ukhcdo.org\/wp-content\/uploads\/2015\/12\/Guidelines_on_genetics_services_for_haemophilia_v5-3_1_final.pdf (2018, accessed November 2022)."},{"key":"bibr14-20406207231165857","volume":"12","author":"Shoukat HMH","year":"2020","journal-title":"Cureus"},{"key":"bibr15-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01561.x"},{"key":"bibr16-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13089"},{"key":"bibr17-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12568"},{"key":"bibr18-20406207231165857","volume":"124","author":"Pavord S","year":"2017","journal-title":"BJOG"},{"key":"bibr19-20406207231165857","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50123"},{"key":"bibr20-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199907000-00009"},{"key":"bibr21-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02074.x"},{"key":"bibr22-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011849"},{"key":"bibr23-20406207231165857","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209619"},{"key":"bibr24-20406207231165857","first-page":"378","volume":"17","author":"Zanon E","year":"2019","journal-title":"Blood Transfus"},{"key":"bibr25-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08545.x"},{"key":"bibr26-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14379"},{"key":"bibr27-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15397"},{"key":"bibr28-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14094"},{"key":"bibr29-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02316.x"},{"key":"bibr30-20406207231165857","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.627715"},{"key":"bibr31-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13461"},{"key":"bibr32-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3402805"},{"key":"bibr33-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13081"},{"key":"bibr34-20406207231165857","volume-title":"Clinical methods: the history, physical, and laboratory examinations","author":"Dodd Wilson I","year":"1990"},{"key":"bibr35-20406207231165857","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242735"},{"key":"bibr36-20406207231165857","unstructured":"European Medicines Agency. Elocta (rFVIIIFc) summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elocta-epar-product-information_en.pdf (2021, accessed November 2022)."},{"key":"bibr37-20406207231165857","unstructured":"Bioverativ Therapeutics Inc. Eloctate\u00ae prescribing information, https:\/\/www.fda.gov\/media\/88746\/download (2020, accessed November 2022)."},{"key":"bibr38-20406207231165857","unstructured":"European Medicines Agency. Alprolix\u00ae summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alprolix-epar-product-information_en.pdf (2021, accessed November 2022)."},{"key":"bibr39-20406207231165857","unstructured":"Bioverativ Therapeutics Inc. Alprolix\u00ae prescribing information, http:\/\/products.sanofi.us\/Alprolix\/alprolix.pdf (2020, accessed November 2022)."},{"key":"bibr40-20406207231165857","unstructured":"European Medicines Agency. Idelvion\u00ae summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/idelvion-epar-product-information_en.pdf (2021, accessed November 2022)."},{"key":"bibr41-20406207231165857","unstructured":"CSL Behring. Idelvion prescribing information, https:\/\/www.idelvion.com\/prescribing-information (2021, accessed November 2022)."},{"key":"bibr42-20406207231165857","unstructured":"Baxalta. Adynovate prescribing information, https:\/\/www.fda.gov\/media\/94470\/download (2021, accessed November 2022)."},{"key":"bibr43-20406207231165857","unstructured":"Novo Nordisk. Esperoct prescribing information, https:\/\/www.fda.gov\/media\/120351\/download (2019, accessed November 2022)."},{"key":"bibr44-20406207231165857","unstructured":"Novo Nordisk. Rebinyn prescribing information, https:\/\/www.novo-pi.com\/rebinyn.pdf (2022, accessed November 2022)."},{"key":"bibr45-20406207231165857","unstructured":"European Medicines Agency. Adynovi summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adynovi-epar-product-information_en.pdf (2022, accessed November 2022)."},{"key":"bibr46-20406207231165857","unstructured":"European Medicines Agency. Esperoct summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/esperoct (2020, accessed November 2022)."},{"key":"bibr47-20406207231165857","unstructured":"European Medicines Agency. Jivi summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jivi-epar-product-information_en.pdf (2021, accessed November 2022)."},{"key":"bibr48-20406207231165857","unstructured":"European Medicines Agency. Refixia summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/refixia-epar-product-information_en.pdf (2022, accessed November 2022)."},{"key":"bibr49-20406207231165857","unstructured":"Bayer Healthcare. Jivi prescribing information, https:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Jivi_PI.pdf (2018, accessed November 2022)."},{"key":"bibr50-20406207231165857","unstructured":"WFH. Online registry of clotting factor concentrates, https:\/\/wfh.org\/article\/wfh-online-registry-of-clotting-factor-concentrates\/#:~:text=The%20Online%20CFC%20Registry%20provides,and%20facilitates%20comparisons%20between%20them (2021, accessed November 2022)."},{"key":"bibr51-20406207231165857","unstructured":"Farrugia A. Guide for the assessment of clotting factor concentrates. 3rd ed. Montreal, QC, Canada: World Federation of Hemophilia, https:\/\/www1.wfh.org\/publication\/files\/pdf-1271.pdf (2017, accessed November 2022)."},{"key":"bibr52-20406207231165857","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6050054"},{"key":"bibr53-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12613"},{"key":"bibr54-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13438"},{"key":"bibr55-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1159\/000488060"},{"key":"bibr56-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13641"},{"key":"bibr57-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"bibr58-20406207231165857","unstructured":"European Medicines Agency. Hemlibra: EPAR-product information, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemlibra#product-information-section (2022, accessed November 2022)."},{"key":"bibr59-20406207231165857","unstructured":"Genetech Inc. Hemlibra\u00ae prescribing information, https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf (2022, accessed November 2022)."},{"key":"bibr60-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1624519"},{"key":"bibr61-20406207231165857","unstructured":"ClinicalTrialsgov. Study identifier NCT04431726. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous emicizumab in participants from birth to 12 months of age with hemophilia A withoutiInhibitors (HAVEN 7), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04431726 (accessed November 2022)."},{"key":"bibr62-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14543"},{"key":"bibr63-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15076"},{"key":"bibr64-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13903"},{"key":"bibr65-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.03.002"},{"key":"bibr66-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002699"},{"key":"bibr67-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001292"},{"key":"bibr68-20406207231165857","unstructured":"ClinicalTrialsgov. Study identifier NCT04759131. Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia A (XTEND-Kids), https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04759131 (accessed November 2022)."},{"key":"bibr69-20406207231165857","unstructured":"ClinicalTrialsgov. Study identifier NCT05053139. A research study investigating Mim8 in adults and adolescents with haemophilia A with or without inhibitors, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05053139 (accessed November 2022)."},{"key":"bibr70-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-512764"},{"key":"bibr71-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.3.874"},{"key":"bibr72-20406207231165857","unstructured":"ClinicalTrials.gov. Study identifier NCT04083781. Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors (explorer7), https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04083781 (accessed November 2022)."},{"key":"bibr73-20406207231165857","unstructured":"ClinicalTrials.gov. Study identifier NCT04082429. Research study to look at how well the drug concizumab works in your body if you have haemophilia without inhibitors (explorer8), https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04082429 (accessed November 2022)."},{"key":"bibr74-20406207231165857","unstructured":"ClinicalTrials.gov. Study identifier NCT03938792. Study of the efficacy and safety PF-06741086 in adult and teenage participants with severe hemophilia A or moderately severe to severe hemophilia B, https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03938792 (accessed November 2022)."},{"key":"bibr75-20406207231165857","unstructured":"ClinicalTrials.gov. Study identifier NCT05145127. Open-label extension study of marstacimab in hemophilia participants with or without inhibitors, https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05145127 (accessed November 2022)."},{"key":"bibr76-20406207231165857","unstructured":"ClinicalTrials.gov. Study identifier NCT03549871. A study of fitusiran in severe hemophilia A and B patients previously receiving factor or bypassing agent prophylaxis (ATLAS-PPX), https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03549871 (accessed November 2022)."},{"key":"bibr77-20406207231165857","unstructured":"ClinicalTrials.gov. Study identifier NCT02554773. An open-label extension study of an investigational drug, fitusiran, in patients with moderate or severe hemophilia A or B, https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02554773 (accessed November 2022)."},{"key":"bibr78-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569"},{"key":"bibr79-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000364"},{"key":"bibr80-20406207231165857","volume":"11","author":"Zhao XY","year":"2020","journal-title":"Nat Commun"},{"key":"bibr81-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.11.006"},{"key":"bibr82-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32722-7"},{"key":"bibr83-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908490"},{"key":"bibr84-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708483"},{"key":"bibr85-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14391"},{"key":"bibr86-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407309"},{"key":"bibr87-20406207231165857","unstructured":"European Medicines Agency. Roctavian. Valoctocogene roxaparvovec, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/roctavian-0 (2022, November 2022)."},{"key":"bibr88-20406207231165857","unstructured":"Food Drug Administration. FDA approves first gene therapy to treat adults with hemophilia B, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treat-adults-hemophilia-b (2022, accessed November 2022)."},{"key":"bibr89-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100759"},{"key":"bibr90-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"bibr91-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14201"},{"key":"bibr92-20406207231165857","unstructured":"PedNet Haemophilia Registry. Protocol of the PedNet haemophilia registry, https:\/\/pednet.eu\/wp-content\/uploads\/2020\/06\/Protocol-of-the-PedNet-Haemophilia-Registry-version-6_05052020.pdf (2020, accessed November 2022)."},{"key":"bibr93-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013563"},{"key":"bibr94-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12412"},{"key":"bibr95-20406207231165857","unstructured":"Kenet G, Nolan B, Oldenburg J, et al. Emicizumab treatment in pediatric haemophilia A patients: >1 year safety based on real-world data from the PedNet cohorts [abstract]. Res Pract Thromb Haemost 2021, https:\/\/abstracts.isth.org\/abstract\/emicizumab-treatment-in-pediatric-haemophilia-a-patients-1-year-safety-based-on-real-world-data-from-the-pednet-cohorts\/"},{"key":"bibr96-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000658"},{"key":"bibr97-20406207231165857","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.239160"},{"key":"bibr98-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01511-8"},{"key":"bibr99-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01497.x"},{"key":"bibr100-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12730"},{"key":"bibr101-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13819"},{"key":"bibr102-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14192"},{"key":"bibr103-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13762"},{"key":"bibr104-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14381"},{"key":"bibr105-20406207231165857","unstructured":"ClinicalTrials.gov. Study identifier NCT04030052. Emicizumab PUPs and Nuwiq ITI study, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04030052 (accessed November 2022)."},{"key":"bibr106-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118492"},{"key":"bibr107-20406207231165857","volume":"5","author":"Jim\u00e9nez-Yuste V","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"bibr108-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14957"},{"key":"bibr109-20406207231165857","unstructured":"ClinicalTrials.gov. Study identifier NCT04204408. A research study investigating Mim8 in people with haemophilia A (FRONTIER1), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04204408 (accessed November 2022)."},{"key":"bibr110-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006403"},{"key":"bibr111-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1854"},{"key":"bibr112-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2017.02.004"},{"key":"bibr113-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13215"},{"key":"bibr114-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12905"},{"key":"bibr115-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14153"},{"key":"bibr116-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13985"},{"key":"bibr117-20406207231165857","first-page":"46","volume":"11","author":"Broderick C.","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"bibr118-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.12727"},{"key":"bibr119-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169880"},{"key":"bibr120-20406207231165857","first-page":"374","volume":"18","author":"Tagliaferri A","year":"2020","journal-title":"Blood Transfus"},{"key":"bibr121-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12433"},{"key":"bibr122-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-528414"},{"key":"bibr123-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718784834"},{"key":"bibr124-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02893.x"},{"key":"bibr125-20406207231165857","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232132"},{"key":"bibr126-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13862"},{"key":"bibr127-20406207231165857","doi-asserted-by":"publisher","DOI":"10.17225\/jhp00178"},{"key":"bibr128-20406207231165857","unstructured":"World Federation of Hemophilia. Education and eLearning, https:\/\/wfh.org\/education-and-elearning\/ (2022, accessed November 2022)."},{"key":"bibr129-20406207231165857","unstructured":"European Haemophilia Consortium. About bleeding disorders, https:\/\/www.ehc.eu\/bleeding-disorders\/about-bleeding-disorders\/ (2019, accessed November 2022)."},{"key":"bibr130-20406207231165857","unstructured":"National Hemophilia Foundation. Bleeding disorders A\u2013Z, https:\/\/www.hemophilia.org\/bleeding-disorders-a-z (2022, accessed November 2022)."},{"key":"bibr131-20406207231165857","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S139851"},{"key":"bibr132-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2019.1687798"},{"key":"bibr133-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15342"},{"key":"bibr134-20406207231165857","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27466"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207231165857","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207231165857","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207231165857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:16:34Z","timestamp":1777590994000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207231165857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":134,"alternative-id":["10.1177\/20406207231165857"],"URL":"https:\/\/doi.org\/10.1177\/20406207231165857","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"20406207231165857"}}